Please find attached herewith the audited standalone & consolidated financial results for the quarter and year ended March 31, 2026
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma Ltd reported robust FY26 results with standalone revenue of Rs. 70,342.54 lakh (up 6.4% YoY) and consolidated revenue of Rs. 84,621.91 lakh (up 4.5% YoY). Standalone net profit grew 48% to Rs. 9,687.44 lakh while consolidated net profit jumped 49% to Rs. 12,563.92 lakh, driven by strong operational performance. The company declared a 100% dividend (Rs. 1 per share) and received an unmodified audit opinion from Kalyaniwalla & Mistry LLP. Exceptional items of Rs. 215.55 lakh (standalone) and Rs. 248.71 lakh (consolidated) were recorded as past service costs due to new labour code implementation. Share-based payment expenses under the ESOP scheme increased significantly to Rs. 862.42 lakh from Rs. 414 lakh, reflecting expanded employee stock option grants. Two new subsidiaries were incorporated in Kenya and DRC during the year.
Strong bottom-line growth of ~49% in consolidated PAT signals operational efficiency and global expansion benefits. The 100% dividend payout and clean audit opinion indicate financial health, though increased ESOP expenses and exceptional items slightly inflate costs.